We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reckitt Benckiser Group Plc | LSE:RB. | London | Ordinary Share | GB00B24CGK77 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6,498.00 | 6,502.00 | 6,506.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
27/7/2018 08:37 | With growth kicking back in fears were clearly overdone and expect price to gradually climb from here back toward its old highs. Nice. | its the oxman | |
27/7/2018 08:07 | Big move up for RB, when the LSE hasn't opened a stock for a few minutes it's going to move big, waiting for that order book to fill up and get the liquidity there. | this_time_its_different | |
25/7/2018 21:44 | I'm equally surprised by the lack of comments.Probably because share price is so large. So not as 'exciting' as penny shares that are apparently about to hit the big time.But I don't mind it being under the radar.First bought at a little under £57 and subsequently topped up. It is doing nicely... | tin5866 | |
17/7/2018 08:27 | IMO brokers seem to changes in the share price rather than predicting it. This is one of my best performers this year as I bought in just after the profit warning. Initially it was more of a trade than a long term hold but I think it will end up as the latter given its defensive nature. I'm always amazed at just how few comments there are on bb's with relatively safe large companies(whilst I accept they are boring they are good investments) - a high risk AIM tiddler will always get more... | dr biotech | |
12/7/2018 13:37 | money seems to be flowing back into 'safe'/defensive stocks like Reckitt and Glaxo currently ... | mister md | |
16/5/2018 15:59 | There is a detailed report on Reckitt Benckiser recent AGM which can be found in our members area here: To access the report, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the report (and reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: | sharesoc | |
24/4/2018 17:11 | Just for fun on a slow wet day I looked at the RB. chart and a giant head and shoulders going back to 2016. If you believe in that chart formation it has a downside of about £47.50. I have never invested in RB. and missed a huge upside from 2005. Is this now getting close to a potential buying point ??? | betman | |
24/4/2018 16:40 | Long may it continue, i want more! | mozy123 | |
24/4/2018 16:28 | You're living in the past, consumer defensives are poison at the moment. | podgyted | |
23/4/2018 11:41 | RB is a solid business and a Buy, especially at these prices. You don't realise the power of brands like Dettol, Durex and Strepsils. RB has been oversold and should easily ride up to £65 with no problems. | this_time_its_different | |
23/4/2018 10:11 | Market open.. On the broker note front, consumer goods giant Reckitt Benckiser was hit by a downgrade to 'market perform' at Raymond James | philanderer | |
21/4/2018 11:05 | Perfect time to buy KMB, JNJ and RB. You always buy into weakness. KMB below $100 is a screaming buy and an instant 30% profit. KMB won't struggle to get back above $130 over the next year or so. | this_time_its_different | |
20/4/2018 21:04 | JnJ, KMB & P&G still heading south. | spacecake | |
20/4/2018 14:23 | spacecake: i like to have my cake and eat it! lol | asturius101 | |
20/4/2018 13:34 | Dip on the US open may be, as per ULVR yesterday. More scaling back on estimates following today?, still around 18x, ulvr on a more generous yield available for about 19x, with arguably a significantly better product portfolio. Not sure I see the value in RB., Others may see it differently. | essentialinvestor | |
20/4/2018 12:39 | The crystal ball is particularly clear today plus the moon is a waxing crescent phase :-) so let see ! | spacecake | |
20/4/2018 12:28 | lol are you sure abt that? huge upward momentum now | asturius101 | |
20/4/2018 12:22 | Come 3pm this will be on the banana slide again, good company but could be cheaper. | spacecake | |
20/4/2018 11:41 | well, happy to add while this share remains unloved. | mister md | |
20/4/2018 10:08 | Reckitt below £55 is extremely cheap, you won't struggle to gain £10-£15 in a few months. Most resistance is after £70. It's an easy £15 buying it now. | this_time_its_different | |
20/4/2018 09:58 | Seems rather cheap to me ... | mister md | |
20/4/2018 09:44 | I bght some @ 5446.00 missed dip of 5255. | action | |
20/4/2018 09:16 | Baby Formula is a solid industry, there will always be new babies and they will need baby formula. My bigger worry is whether supermarket generics are outselling brand names, but right now, supermarket generics lack quality. Reckitt's products are all quality and their marketing is top notch, they did overpay for Mead and we are seeing the consequences now. Reckitt shareholders are not used to these kind of drops, something similar happened in 1998, so there is a lot of panic selling as well. The stock needs time to stabilise and forget 2017 ever happened. | this_time_its_different | |
20/4/2018 09:09 | Unless Mead is going bad and they grossly overpaid | toffeeman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions